Multi-variant Genetic Panel for Genetic Risk of Opioid Addiction.

Area of Science:

• Genetics
• Neuroscience
• Pharmacology

Background:

• Chronic pain and prescription dependence affect over 116 million globally.
• Opioids cause the majority of overdose deaths in the US, with nearly 2 million Americans dependent in 2014.
• Genetic factors are implicated in the development of opioid addiction.

Purpose of the Study:

• To identify genetic variations associated with opioid addiction.
• To develop a predictive model for assessing opioid addiction risk.
• To inform therapeutic decisions by identifying patients at lower risk.

Main Methods:

• A case cohort study compared 16 single nucleotide polymorphisms (SNPs) in brain reward pathways between opioid-addicted individuals and controls.
• A predictive score was developed using data from 37 addicted patients and 30 controls.
• The model's generalizability was tested on an additional 138 samples.

Main Results:

• The predictive model demonstrated high accuracy in both derivation (ROC=0.92, sensitivity=92%, specificity=90%) and generalizability datasets (sensitivity=97%, specificity=87%).
• A negative likelihood ratio of 0.03 suggests the model can effectively exclude individuals at high risk for opioid addiction.
• The model's findings support its use as an evidence-based tool in clinical decision-making.

Conclusions:

• Genetic variations can be utilized to predict the risk of opioid addiction.
• The developed predictive model shows significant potential for clinical application.
• Identifying lower-risk individuals can optimize treatment strategies and mitigate the opioid crisis.